Feasibility of oncology clinical trial-embedded evaluation of social determinants of health.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
11 2022
Historique:
revised: 25 07 2022
received: 11 04 2022
accepted: 29 07 2022
pubmed: 8 9 2022
medline: 1 10 2022
entrez: 7 9 2022
Statut: ppublish

Résumé

Social determinants of health (SDoH) are associated with stark disparities in cancer outcomes, but systematic SDoH data collection is virtually absent from oncology clinical trials. Trial-based SDoH data are essential to ensure representation of marginalized populations, contextualize outcome disparities, and identify health-equity intervention opportunities. We report the feasibility of a pediatric oncology multicenter therapeutic trial-embedded SDoH investigation. Among 448 trial participants, 392 (87.5%) opted-in to the embedded SDoH study; 375 (95.7%) completed baseline surveys, with high longitudinal response rates (88.9-93.1%) over 24 months. Trial-embedded SDoH data collection is feasible and acceptable and must be consistently included within future oncology trials.

Identifiants

pubmed: 36069432
doi: 10.1002/pbc.29933
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e29933

Subventions

Organisme : NCI NIH HHS
ID : K07 CA211847
Pays : United States

Informations de copyright

© 2022 Wiley Periodicals LLC.

Références

Aristizabal P, Winestone LE, Umaretiya P, Bona K. Disparities in pediatric oncology: the 21st century opportunity to improve outcomes for children and adolescents with cancer. Am Soc Clin Oncol Educ Book. 2021;41:e315-e326.
Bona K, Li Y, Winestone L, et al. Poverty and targeted immunotherapy: survival in children's oncology group clinical trials for high-risk neuroblastoma. J Natl Cancer Inst. 2021;113(3):282-291.
Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:1.
Wolfson JA, Bhatia S, Ginsberg J, et al. Expenditures among young adults with acute lymphoblastic leukemia by site of care. Cancer. 2021;127(11):1901-1911.
Aristizabal P, Singer J, Cooper R, et al. Participation in pediatric oncology research protocols: racial/ethnic, language and age-based disparities. Pediatr Blood Cancer. 2015;62(8):1337-1344.
Kahn JM, Kelly KM, Pei Q, et al. Survival by race and ethnicity in pediatric and adolescent patients with hodgkin lymphoma: a children's oncology group study. J Clin Oncol. 2019;37(32):3009-3017.
Winestone LE, Getz KD, Miller TP, et al. The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. Am J Hematol. 2017;92(2):141-148.
Gupta S, Teachey DT, Devidas M, et al. Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. Blood. 2021; 138 (Suppl 1):211.
Fleisch Marcus A, Illescas AH, Hohl BC, Llanos AAM. Relationships between social isolation, neighborhood poverty, and cancer mortality in a population-based study of US adults. PLOS ONE. 2017;12(3):e0173370.
Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol. 2019;5(10):e191870-e191870.
Kahn JM, Gray II DM, JM Oliveri, CM Washington, CR DeGraffinreid, ED Paskett. Strategies to improve diversity, equity, and inclusion in clinical trials. Cancer. 2022;128(2):216-221.
Zheng DJ, Shyr D, Ma C, Muriel AC, Wolfe J, Bona K. Feasibility of systematic poverty screening in a pediatric oncology referral center. Pediatr Blood Cancer. 2018;65:e27380.
Bona K, London WB, Guo D, Frank DA, Wolfe J. Trajectory of material hardship and income poverty in families of children undergoing chemotherapy: a prospective cohort study. Pediatr Blood Cancer. 2016;63(1):105-111.
Children's defense fund (CDF). The State of America's Children. 2021; https://www.childrensdefense.org/state-of-americas-children/
Ilowite MF, Al-Sayegh H, Ma C, et al. The relationship between household income and patient-reported symptom distress and quality of life in children with advanced cancer: a report from the PediQUEST study. Cancer. 2018;124(19):3934-3941.
Umaretiya PJ, Koch VB, Stevenson KE, et al. Household material hardship and parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia. J Clin Oncol. 2021;39(15):10025-10025.
Muffly L, Tardif C, de Souza J. Financial toxicity in children, adolescent, and young adult cancer patients and their families: a large national registry analysis from the family reach foundation. J Clin Oncol. 2016;34:6615-6615. 15_suppl.
Roser K, Erdmann F, Michel G, Winther JF, Mader L. The impact of childhood cancer on parents' socio-economic situation-a systematic review. Psycho-Oncology. 2019;28(6):1207-1226.
Umaretiya PJ, Revette A, Seo A, et al. PediCARE: development of a poverty-targeted intervention for pediatric cancer. Pediatr Blood Cancer. 2021;68(10):e29195.

Auteurs

Rahela Aziz-Bose (R)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.

Daniel J Zheng (DJ)

Divisions of Hematology and Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Puja J Umaretiya (PJ)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Lenka Ilcisin (L)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
Department of Pediatric Surgery, Boston Children's Hospital, Boston, Massachusetts, USA.
Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Kristen Stevenson (K)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Victoria Koch (V)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Ariana Valenzuela (A)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Peter D Cole (PD)

Division of Pediatric Hematology/Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.

Lisa M Gennarini (LM)

Division of Pediatric Hematology/Oncology and Blood & Marrow Cell Transplantation, Montefiore Medical Center, Bronx, New York, USA.

Justine M Kahn (JM)

Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Columbia University Irving Medical Center, New York, New York, USA.

Kara M Kelly (KM)

Department of Pediatrics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

Thai-Hoa Tran (TH)

Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Ste-Justine, University of Montreal, Montreal, QC, Canada.

Bruno Michon (B)

Department of Pediatrics, Centre Hospitalier Universitaire de Quebec, Saint-Foy, QC, Canada.

Jennifer J G Welch (JJG)

Division of Pediatric Hematology/Oncology, Hasbro Children's Hospital/Brown University, Providence, Rhode Island, USA.

Lewis B Silverman (LB)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.

Joanne Wolfe (J)

Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Kira Bona (K)

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.
Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH